<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04471792</url>
  </required_header>
  <id_info>
    <org_study_id>1150</org_study_id>
    <nct_id>NCT04471792</nct_id>
  </id_info>
  <brief_title>Creatine Use and Muscle Stretching in Peripheral Artery Disease</brief_title>
  <official_title>Creatine Monohydrate Use and Muscle Stretching in Peripheral Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Florida State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To utilize near-infrared spectroscopy to investigate if our research device, which induces
      muscle stretching, and creatine loading impact submaximal exercise performance in aged and
      PAD patients. Near-infrared spectroscopy (NIRS)-derived tissue oxygenation responses will be
      obtained during device placement (muscle stretch) and during a walking test (i.e., six-minute
      walk test). We will also assess muscle oxygenation at rest and during device placement with
      Magnetic Resonance Imaging. It is hypothesized that the stretching protocol will improve both
      NIRS-derived tissue oxygenation and magnetic resonance-derived muscle oxygenation and that
      creatine supplementation will further improve phosphorus metabolite muscle performance. All
      patients will undergo either 4 weeks of stretch training with- or- without creatine
      supplementation according to previously defined creatine guidelines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lower extremity peripheral artery disease (PAD) has been estimated to impact nearly 8.5
      million U.S. adults above the age of 40, significantly increasing the rate of morbidity and
      mortality with concomitant decreases in quality of life. These patients are often given
      medical therapy (e.g., statins, antiplatelet, anticoagulants) and are also recommended to
      begin structured exercise programs. However, the limb ischemia that occurs during physical
      activity in these patients often limits exercise tolerance. A previous study by Bauer and
      colleagues showed that impaired muscle metabolism is a major contributor to functional
      limitations in PAD patients. These data are important in that they show alterations in blood
      flow and metabolic machinery likely impact exercise tolerance. As such, the development of
      tolerable countermeasures to improve limb blood flow and muscle energetics may increase
      adherence to exercise therapy and improve health outcomes in PAD patients. Previous work by
      the investigators has shown that daily muscle stretching, achieved via 30-minutes of ankle
      dorsiflexion, significantly improved soleus muscle function and muscle blood flow during
      exercise in a rat model of aging . In a follow-up study, the investigators have also shown
      that this model improves vascular function and walking function in PAD patients. As noted
      above, muscle energetics are delayed in PAD patients, so improving the rest-to-exercise
      transition with creatine supplementation may help PAD patients sustain exercise longer. The
      investigators are now testing to see if an added supplement can further improve the effects
      of muscle stretching in PAD patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 20, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 29, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomized, double-blind research design.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Walking tolerance</measure>
    <time_frame>4 weeks</time_frame>
    <description>All patients will perform a pre -and -post 6 minute walking test to assess functional outcomes of muscle stretching and supplementation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Near infrared spectroscopy (NIRS)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Use of NIRS on the lateral head of the gastrocnemius muscle in all patients will be performed. NIRS will be measured during a vascular occlusion test, during placement of splint device, and the 6 minute walking test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Use of MRI to assess muscle oxygenation during a vascular occlusion test at rest, and during placement of splint device</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Creatine monohydrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Creatine Monohydrate will be given at a 5 day loading period (10g/day) followed by a maintenance phase (5 g/day). The objectives of the current trial are to investigate if creatine supplementation plus muscle stretching improves 6-minute walking distance and muscle oxygenation in patients with peripheral artery disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cellulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>These participants will consume a fiber supplement in place of creatine monohydrate at a matched dose with muscle stretching.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Creatine monohydrate</intervention_name>
    <description>Creatine monohydrate will be used in combination with muscle stretching.</description>
    <arm_group_label>Creatine monohydrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cellulose</intervention_name>
    <description>Cellulose will be used in combination with muscle stretching.</description>
    <arm_group_label>Cellulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Resting ankle-brachial index of less than 0.90

          2. Clinical diagnosis by a medical professional

          3. Stable condition for at least 3 months

        Exclusion Criteria:

          1. Habitual exercise or cardiovascular rehabilitation program during the past 3 months

          2. Critical limb ischemia

          3. Amputation

          4. Leg pain at rest

          5. Major surgery in the last 3 months

          6. Joint or muscle range of motion issues

          7. Requirement of supplemental oxygen

          8. Heart Failure

          9. Atrial fibrillation

         10. Wheelchair confinement or inability to walk

         11. Reynaud's disease

         12. Pacemaker or pacer wires

         13. Open heart surgery

         14. Artificial heart valves

         15. Aortic aneurysm clips

         16. Cochlear implants (hearing device)

         17. Braces or extensive dental work

         18. Implanted electrical or mechanical devices

         19. Tissue expanders

         20. Foreign metal objects from explosives

         21. Shrapnel or metalwork fragments in eyes/skin/body

         22. Artificial limbs

         23. Pregnant

         24. Claustrophobic

         25. Have tremors or cannot lie still for 1-2 hours

         26. History of being a metal worker/welder

         27. History of eye surgery/eyes washed out because of metal

         28. Birth control devices (I.U.D.)

         29. A shunt (ventricular or spinal)

         30. Metal plates/pins/screws/wires

         31. Neuro/bio-stimulators (TENS unit)

         32. Vision problems uncorrectable with lenses

         33. Claustrophobia

         34. Prior neurosurgery

         35. Older tattoos with metal dyes

         36. Unwillingness to remove nose, ear, tongue or face jewelry

         37. History of renal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judy Muller-Delp, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judy Muller-Delp, Ph.D.</last_name>
    <phone>850-645-1868</phone>
    <email>judy.delp@med.fsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacob Caldwell, Ph.D.</last_name>
    <phone>248-469-2058</phone>
    <email>jacob.caldwell@med.fsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Florida State University</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Muller-Delp</last_name>
      <phone>850-645-1868</phone>
      <email>judy.delp@med.fsu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hultman E, SÃ¶derlund K, Timmons JA, Cederblad G, Greenhaff PL. Muscle creatine loading in men. J Appl Physiol (1985). 1996 Jul;81(1):232-7.</citation>
    <PMID>8828669</PMID>
  </reference>
  <reference>
    <citation>Hotta K, Behnke BJ, Arjmandi B, Ghosh P, Chen B, Brooks R, Maraj JJ, Elam ML, Maher P, Kurien D, Churchill A, Sepulveda JL, Kabolowsky MB, Christou DD, Muller-Delp JM. Daily muscle stretching enhances blood flow, endothelial function, capillarity, vascular volume and connectivity in aged skeletal muscle. J Physiol. 2018 May 15;596(10):1903-1917. doi: 10.1113/JP275459. Epub 2018 Apr 5.</citation>
    <PMID>29623692</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Florida State University</investigator_affiliation>
    <investigator_full_name>Judy Delp</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Muscle stretch</keyword>
  <keyword>Creatine Monohydrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

